Effects of common antitussive drugs on the hERG potassium channel current

Journal of Cardiovascular Pharmacology

Volumn 52, Issue 6, 2008, Pages 494-499

  Deisemann, Heike ^a   Ahrens, Nadine ^a   Schlobohm, Irene ^a   Kirchhoff, Christian ^a   Netzer, Rainer ^a   Möller, Clemens ^a  

^a EVOTEC AG   (Germany)

Author keywords

Antitussive; Clobutinol; HERG; QT prolongation; Torsade de pointes

Indexed keywords

CLOBUTINOL; CODEINE; DEXTROMETHORPHAN; MORPHINE; PENTOXYVERINE; POTASSIUM CHANNEL HERG; THEOBROMINE; AMINOALCOHOL; ANTITUSSIVE AGENT; CYCLOPENTANE DERIVATIVE; ERG1 POTASSIUM CHANNEL; POTASSIUM; POTASSIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; IC 50; MAXIMUM PLASMA CONCENTRATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; CELL MEMBRANE POTENTIAL; CHEMICALLY INDUCED DISORDER; CHO CELL; COMPARATIVE STUDY; CRICETULUS; DOSE RESPONSE; DRUG ANTAGONISM; GENETIC TRANSFECTION; GENETICS; HAMSTER; METABOLISM; TIME; TORSADE DES POINTES;

AMINO ALCOHOLS; ANIMALS; ANTITUSSIVE AGENTS; CHO CELLS; CODEINE; CRICETINAE; CRICETULUS; CYCLOPENTANES; DEXTROMETHORPHAN; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; MEMBRANE POTENTIALS; POTASSIUM; POTASSIUM CHANNEL BLOCKERS; THEOBROMINE; TIME FACTORS; TORSADES DE POINTES; TRANSFECTION;

EID: 59449101991     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31818eec8d     Document Type: Article

References (19)

1. Cherry DK, Burt CW, Woodwell, DA. National ambulatory medical care survey: 2001 summary. Adv Data. 2003;337:1-44.
2. Bellocq C, Wilders R, Schott JJ, et al. A common antitussive drug, clobutinol, precipitates the long QT syndrome 2. Mol Pharmacol. 2004; 66:1093-1102.
3. Boehringer Ingelheim GmbH. Expert statement on the non-clinical and clinical evaluation of the potential for delayed ventricular repolarization (QT Interval Prolongation) by clobutinol. Doc. No.: U07-0134. Boehringer Ingelheim GmbH; 2007.
4. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channel and cardiac arrhythmia. Nature. 2006;440:463-469.
5. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): The Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolariza-tion (QT Interval Prolongation) By Human Pharmaceuticals. S7B. Step 4; 12 May 2005.
6. Usmani OS, Belvisi MG, Patel HJ, et al. Theobromine inhibits sensory nerve activation and cough. FASEB J. 2005;19:231-233.
7. Hamill OP, Marty A, Neher E, et al. Improved patch clamp techniques for high-resolution current recording from cells and cell-free membrane-patches. Pflügers Arch. 1981;391:85-100.
8. Katchman AN, Koerner J, Tosaka T, et al. Comparative evaluation of hERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther. 2006; 316:1098-1106.
9. Lu HR, Vlaminckx E, Van Ammel K, et al. Drug-induced long QT in isolated rabbit Purkinje fibers: importance of action potential duration, triangulation and early afterdepolarizations. Eur J Pharmacol. 2002;452: 183-192.
10. Martin RL, McDermott JS, Salmen HJ, et al. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. J Cardiovasc Pharmacol. 2004;43: 369-379.
11. Cavero I, Mestre M, Guillon JM, et al. Drugs that prolong QT interval as an unwanted side effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. Exp Opin Pharmacother. 2000;1:947-973.
12. De Ponti F, Poluzzi E, Cavalli A, et al. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce Torsade de Pointes. Drug Safety. 2002;25:263-286.
13. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003; 58:32-45.
14. Regenthal R, Krueger M, Koeppel C, et al. Drug levels: therapeutic and toxic serum/plasma concentrations of common drugs. J Clin Monit. 1999; 15:529-544.
15. Margulis M, Sorota S. Additive effects of combined application of multiple hERG blockers. J Cardiovasc Pharmacol. 2008;51:549-552.
16. Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351:1089-1096.
17. Drug card for Morphine (DB00295). Available at: http://redpoll.pharma-cy. ualberta.ca/drugbank/. Accessed: February 11, 2008.
18. Quiding H, Anderson P, Bondesson U, et al. Plasma concentrations of codeine and its metabolite, morphine, after single and repeated oral administration. Eur J Clin Pharmacol. 1986;30:673-677.
19. Katchman AN, McGroary KA, Kilborn MJ, et al. Influence of opioid agonists on cardiac human ether-a-go-go related gene K+ currents. J Pharmacol Exp Ther. 2002;303:688-694.